光银国际助力赛目科技于香港主板成功上市

2025年1月15日，光银国际作为独家保荐人、联席整体协调人、联席全球协调人、联席账簿管理人、联席牵头经办人及资本市场中介人，成功助力北京赛目科技股份有限公司（股票代号：2571.HK，以下简称“赛目科技”）于香港主板挂牌上市。

赛目科技是中国一家专注于智能网联汽车（「ICV」）仿真测试技术的科技公司，主要从 事ICV仿真测试产品的设计及研发并提供相关测试、验证和评价解决方案。ICV指配备先进的车载传感器、控制器、制动器及其他装置，整合先进的通信及网络技术。根据弗若斯特沙利文的资料，按2023年的收入计，公司是中国ICV测试、验证和评价解决方案行业的最大市场参与者，市场份额约为5.3%，而按2023年的收入计，公司是中国ICV仿真测试软件及平台市场的最大市场参与者，市场份额约为5.9%。公司也是中国几家能够提供一站式ICV测试、验证和评价解决方案的市场参与者之一。

此次IPO募集资金将用于提升公司的研发能力、地域扩张及提升公司的销售及营销能力，以及一般企业用途及营运资金。

光银国际作为此次IPO项目的独家保荐人、联席整体协调人、联席全球协调人、联席账簿管理人、联席牵头经办人及资本市场中介人，为公司成功挂牌上市保驾护航，做出了重要的贡献。光银国际凭借在香港资本市场的深厚经验，在此次项目保荐执行、市场推介、监管沟通等方面起到了至关重要的作用。

在保荐工作方面，光银国际牵头协助公司开展各条线工作，确保满足IPO发行各项要求，高效配合发行人落地香港上市执行，为项目的顺利审批和成功发行奠定了坚实的基础，协助公司灵活高效地解决问题，助力公司顺利上市。市场推介方面，光银国际充分调动体系内多平台、多渠道的资源，对投资者进行全面的覆盖与充分的教育，向投资者传递公司独特的投资价值及未来的增长潜力，于发行前识别投资者的参与意向，协助公司引入高质量基石投资者，为项目顺利按时间表推进簿记奠定坚实基础。

As the Sole Sponsor, Joint Overall Coordinator, Joint Global Coordinator, Joint Bookrunner, Joint Lead Manager and Capital Market Intermediary, CEBI assisted Beijing Saimo Technology Co., Ltd. (Stock Code: 2571.HK, “SAIMO”) to get listed on the Main Board of the Stock Exchange of Hong Kong on 15th January 2025.

SAIMO is a technology company in the PRC focusing on intelligent connected vehicle (“ICV”) simulation testing technologies, and primarily engaged in the design and R&D of ICV simulation testing products and the provision of related testing, validation and evaluation solutions. ICVs refer to a new generation of vehicles that are equipped with advanced on-board sensors, controllers, actuators and other devices, and integrating advanced communication and network technologies. According to F&S, the company is the largest market player in China’s ICV testing, validation and evaluation solutions industry with a market share of approximately 5.3% in terms of revenue in 2023, and the largest market player in China’s ICV simulation testing software and platforms market with a market share of approximately 5.9% in terms of revenue in 2023. The company is also one of the several market players capable of providing one-stop ICV testing, validation and evaluation solutions in China.

The net proceeds from the Global Offering will be used for enhancing R&D capabilities, geographic expansion and enhancing sales and marketing efforts, and general corporate purposes and working capital.

As a Sole Sponsor, Joint Overall Coordinator, Joint Global Coordinator, Joint Bookrunner, Joint Lead Manager and Capital Market Intermediary, CEBI has made crucial contributions to the successful listing of the Company. CEBI’s extensive experience in the Hong Kong equity market, especially in the field of sponsor execution, marketing and investor targeting, as well as communication with regulatory parties has played an important role through the entire IPO.

In terms of sponsor work, CEBI has taken lead to initiate various IPO tasks for the sake of satisfying the IPO requirements and effectively meet the IPO timetable, which are strong foundations for smooth approvals and successful issuance. These in turns demonstrate the flexible problem-solving skills. In terms of marketing activities, CEBI has fully utilize multiple platforms and channels available in order to achieve a comprehensive coverage of investors and sufficient investor education. These would help to promote the unique investment highlights of the Company, as well as its growth potentials, which is expected to eventually help identifying potential investors’ subscription intension, thus assist the Company to bring in high-quality Cornerstone Investors and push the IPO timetable forward together,